Lexeo Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its gene therapy candidate LX2020 for treating PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). This designation is based on promising interim data from an ongoing Phase I/II clinical trial and highlights LX2020's potential to address the genetic cause of this serious heart disease. LX2020 also holds Orphan Drug and Fast Track statuses, which may accelerate its development and review. Lexeo plans to provide further clinical and regulatory updates later this year as it advances this one-time gene therapy for a condition with no current disease-modifying treatments.
Berlin's state government refused to pay a 30 Bitcoin ransom (about $2.4 million) demanded by the Rhysida ransomware group, leading to the release of 5.7 terabytes of stolen data on the dark web. The cyberattack, detected on August 14, disrupted two ...
Bitcoin traded near $79,972, up 0.43% in 24 hours, with optimism for reaching $85,000 fueled by strong ETF inflows and bullish market sentiment. The global crypto market cap rose to $2.72 trillion, led by gains in Solana, Ethereum, XRP, and BNB. Key ...
OPEC+ decided to keep its oil production unchanged for October, awaiting a full review of member capacities before setting new 2027 quotas. The ongoing Iran war disrupts exports through the Strait of Hormuz, limiting OPEC+'s ability to meet productio...
On September 3, 2026, XRP Healthcare wallets were hacked, resulting in the theft of approximately 267,000 XRP and millions of related tokens. The breach exploited a critical security flaw involving users' private seed phrases, which were exposed when...
Dogecoin has surged past its 200-day moving average, approaching the key $0.10 resistance level after a strong rally from around $0.08. This breakout strengthens its short-term bullish outlook, with technical patterns suggesting potential further gai...
